Evacuant

Details Evacuant Evacuant

1999-11-23

2002-08-20

Pak, John (Department: 1616)

Drug, bio-affecting and body treating compositions

Inorganic active ingredient containing

Aluminum, calcium or magnesium element, or compound containing

C424S400000, C424S439000, C424S451000, C424S464000, C424S466000, C424S489000, C424S499000, C424S093100, C424S093300, C424S093400, C424S093450, C424S093510, C424S195160, C424S780000, C514S023000, C514S053000, C514S470000, C514S557000, C514S819000, C514S892000, C514S925000, C514S951000, C514S952000

Reexamination Certificate

active

06436447

ABSTRACT:

BACKGROUND OF THE INVENTION
The present invention relates to an evacuant utilizable for constipation or evacuation of bowel contents, and more particularly, it relates to an evacuant of magnesium type possessing a satisfactory evacuating effect in a smaller dose substantially without accompanying irritation to bowel unlike a conventional evacuant of magnesium type heretofore known to exhibit evacuating effect only in a relatively large dose.
From the past, known as an evacuant are tablets or semi-liquid preparations comprised of magnesium oxide or magnesium hydroxide as a main ingredient and incorporated with a binding agent, a disintegrating agent, etc. In case of evacuants of this type, however, it was necessary to take them in a greater dose increased in its weight for achieving a satisfactory evacuating effect so that it was very inconvenient to take such a greater dose of the evacuant. Such conventional evacuant irritates bowel to cause peristalic movement for acceleration of evacuating action, thus resulting in side-effects such as bellyache and intestinal damage for the sake of long-term administration. It can hardly be said therefore that conventional evacuants are taken safely for health.
In order to solve these-problems, the present inventors already developed an evacuant comprises of magnesium oxide, a binder capable of displaying evacuating effect and a disintegrating agent capable of exhibiting evacuating effect and applied for a patent (Japanese Laid-open Patent Appln. No. Hei. 9-40561).
As a result of the present inventors further research made by tracing the gist of the above patent application for developing a more effective evacuant which is reduced in its weight for facilitating oral administration, it has now been found surprisingly that an evacuant containing magnesium oxide of a specific BET value (unit: m
2
/g; referred to hereinafter simply as “BET value”; this BET value is well understood as “surface area” of a solid substance such as a solid catalyst and can be measured according to the so-called BET method using a gas adsorption for determination of a catalyst activity) as an effective ingredient shows an excellent acid reactivity as well as a selectively good evacuating effect and possesses an activity for promoting evacuating action without accompanying any side-effect even after administration for a long period of time, unlike preparations widely utilizable as an evacuant from the past which irritate bowel directly. The present invention has been accomplished on the basis of the above finding.
SUMMARY OF THE INVENTION
It is an object of the present invention to provide an evacuant easily capable of oral administration which exhibits an evacuating effect satisfactorily in a smaller dose without irritating bowel.
It is another object of the present invention to provide an evacuant capable of making the action of good (character) bacteria prevailing to keep the environment of bowel well thereby extremely suppressing odor of feces or stool, which comprised of the aforesaid specific magnesium oxide incorporated with lactic acid bacteria, especially a mixture of sporolactobacteria such as
Sporolactobacillus inulinus
and an yeast extracts and/or an oligosaccharide.
Other and further objects, features and advantages of the present invention will become apparent more fully as the description proceeds.


REFERENCES:
patent: 4458030 (1984-07-01), Manabe et al.
patent: 09 040561 (1997-02-01), None
AHFS 94 Drug Information, American Society of Hospital Pharmacists, Maryland, pp. 1870-1874, 1994.*
Calis S. et al.: “In vitro adsorption of propranolol hydrochloride by various antacids”, Drug Development and Industrial; Pharmacy vol. 12, No. 11-13, 1986, pp. 1833-1845, XP000892398.
Miyasaka K. et al.: “A modified penetration rate method for measuring the wettability of magnesium oxide powders”, Chemical and Pharmaceutical Bulletin, vol. 24, No. 2, 1976, pp. 330-336, XP002133697.
Database WPI Section Ch, Week 199716 Derwent Publications Ltd., London, GB; Class A96, AN 1997-175601, XP002133698 (1997).
Rizkalla N. et al.: “Influence of the fractal character of model substances on their reactivity at solid-liquid interfaces”, Journal of Colloid and Interface Science vol. 215, No. 1, Jul. 1999, pp. 43-53, XP000892572.

Affiliated with

Also associated with

Rating

Evacuant does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Evacuant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Evacuant will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2906923